Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLUSTOID Phleum pratense dose-finding study in grass pollen allergy
2021-006533-19Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Oct 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in grass pollen allergy, allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing CLUSTOID Phleum pratense dose arm(s) with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2022; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
grass pollen allergyallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2021-006533-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006533-19.